These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 30143008)

  • 1. Clinical significance of hyaluronan levels and its pro-osteogenic effect on mesenchymal stromal cells in myelodysplastic syndromes.
    Fei CM; Guo J; Zhao YS; Zhao SD; Zhen QQ; Shi L; Li X; Chang CK
    J Transl Med; 2018 Aug; 16(1):234. PubMed ID: 30143008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Chidamide Promotes Osteogenic Differentiation of Bone Marrow Mesenchymal Stromal Cells from Patients with Myelodysplastic Syndromes].
    Zhao SD; Guo J; Zhao YS; Chang CK
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Apr; 32(2):512-519. PubMed ID: 38660860
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mesenchymal stromal cells from myelodysplastic and acute myeloid leukemia patients display in vitro reduced proliferative potential and similar capacity to support leukemia cell survival.
    Corradi G; Baldazzi C; Očadlíková D; Marconi G; Parisi S; Testoni N; Finelli C; Cavo M; Curti A; Ciciarello M
    Stem Cell Res Ther; 2018 Oct; 9(1):271. PubMed ID: 30359303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Study on phenotypic and cytogenetic characteristics of bone marrow mesenchymal stem cells in myelodysplastic syndromes].
    Song LX; Guo J; He Q; Yang LP; Gu SC; Zhang Z; Zhang X; Wu LY; Li X; Chang CK
    Zhonghua Xue Ye Xue Za Zhi; 2013 Feb; 34(2):127-32. PubMed ID: 23611219
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DICER1 gene and miRNA dysregulation in mesenchymal stem cells of patients with myelodysplastic syndrome and acute myeloblastic leukemia.
    Ozdogan H; Gur Dedeoglu B; Oztemur Islakoglu Y; Aydos A; Kose S; Atalay A; Yegin ZA; Avcu F; Uckan Cetinkaya D; Ilhan O
    Leuk Res; 2017 Dec; 63():62-71. PubMed ID: 29102598
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impaired osteogenic differentiation of mesenchymal stem cells derived from bone marrow of patients with lower-risk myelodysplastic syndromes.
    Fei C; Zhao Y; Gu S; Guo J; Zhang X; Li X; Chang C
    Tumour Biol; 2014 May; 35(5):4307-16. PubMed ID: 24443267
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Common and different alterations of bone marrow mesenchymal stromal cells in myelodysplastic syndrome and multiple myeloma.
    Choi H; Kim Y; Kang D; Kwon A; Kim J; Min Kim J; Park SS; Kim YJ; Min CK; Kim M
    Cell Prolif; 2020 May; 53(5):e12819. PubMed ID: 32372504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inappropriate Notch activity and limited mesenchymal stem cell plasticity in the bone marrow of patients with myelodysplastic syndromes.
    Varga G; Kiss J; Várkonyi J; Vas V; Farkas P; Pálóczi K; Uher F
    Pathol Oncol Res; 2007; 13(4):311-9. PubMed ID: 18158566
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Expression of SDF-1 gene in bone marrow mesenchymal stem cells of patients with myelodysplastic syndrome].
    Zhang YZ; DA WM
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Apr; 14(2):281-4. PubMed ID: 16638197
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bone marrow mesenchymal stromal cell-derived extracellular matrix displays altered glycosaminoglycan structure and impaired functionality in Myelodysplastic Syndromes.
    Bains AK; Behrens Wu L; Rivière J; Rother S; Magno V; Friedrichs J; Werner C; Bornhäuser M; Götze KS; Cross M; Platzbecker U; Wobus M
    Front Oncol; 2022; 12():961473. PubMed ID: 36158640
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mesenchymal stromal cell density is increased in higher grade myelodysplastic syndromes and independently predicts survival.
    Johnson RC; Kurzer JH; Greenberg PL; Gratzinger D
    Am J Clin Pathol; 2014 Dec; 142(6):795-802. PubMed ID: 25389333
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impairment of PI3K/AKT and WNT/β-catenin pathways in bone marrow mesenchymal stem cells isolated from patients with myelodysplastic syndromes.
    Falconi G; Fabiani E; Fianchi L; Criscuolo M; Raffaelli CS; Bellesi S; Hohaus S; Voso MT; D'Alò F; Leone G
    Exp Hematol; 2016 Jan; 44(1):75-83.e1-4. PubMed ID: 26521017
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of bladder-derived acellular matrix, growth factors, and extracellular matrix constituents on the survival and multipotency of marrow-derived mesenchymal stem cells.
    Antoon R; Yeger H; Loai Y; Islam S; Farhat WA
    J Biomed Mater Res A; 2012 Jan; 100(1):72-83. PubMed ID: 21972045
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Osteogenic Differentiation Potential of Bone Marrow Mesenchymal Stem Cells in Patients with Myelodysplastic Syndromes].
    Fei CM; Gu SC; Zhao YS; Guo J; Li X; Chang CK
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Jun; 23(3):750-5. PubMed ID: 26117031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insufficient stromal support in MDS results from molecular and functional deficits of mesenchymal stromal cells.
    Geyh S; Oz S; Cadeddu RP; Fröbel J; Brückner B; Kündgen A; Fenk R; Bruns I; Zilkens C; Hermsen D; Gattermann N; Kobbe G; Germing U; Lyko F; Haas R; Schroeder T
    Leukemia; 2013 Sep; 27(9):1841-51. PubMed ID: 23797473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The different immunoregulatory functions on dendritic cells between mesenchymal stem cells derived from bone marrow of patients with low-risk or high-risk myelodysplastic syndromes.
    Wang Z; Tang X; Xu W; Cao Z; Sun L; Li W; Li Q; Zou P; Zhao Z
    PLoS One; 2013; 8(3):e57470. PubMed ID: 23469196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Cytogenetic characteristics of hematopoietic and stromal progenitor cells in myelodysplastic syndrome].
    Pimenova MA; Parovichnikova EN; Kokhno AV; Domracheva EV; Manakova TE; Mal'tseva IuS; Konnova ML; Shishigina LA; Savchenko VG
    Ter Arkh; 2013; 85(7):34-42. PubMed ID: 24137945
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Osteogenic commitment of Wharton's jelly mesenchymal stromal cells: mechanisms and implications for bioprocess development and clinical application.
    Cabrera-Pérez R; Monguió-Tortajada M; Gámez-Valero A; Rojas-Márquez R; Borràs FE; Roura S; Vives J
    Stem Cell Res Ther; 2019 Nov; 10(1):356. PubMed ID: 31779673
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro study of biological characteristics of mesenchymal stem cells in patients with low-risk myelodysplastic syndrome.
    Zhang YZ; Zhao DD; Han XP; Jin HJ; Da WM; Yu L
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Aug; 16(4):813-8. PubMed ID: 18718067
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Senescence of bone marrow mesenchymal stromal cells is accompanied by activation of p53/p21 pathway in myelodysplastic syndromes.
    Fei C; Zhao Y; Guo J; Gu S; Li X; Chang C
    Eur J Haematol; 2014 Dec; 93(6):476-86. PubMed ID: 24889123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.